Pembrolizumab (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/11/2018|
|Rapid review completed||07/12/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||19/12/2018|
|Pre-submission consultation with Applicant||14/01/2019|
|Submission received from Applicant||16/07/2019|
|Preliminary review sent to Applicant||13/11/2019|
|NCPE assessment recommenced||12/12/2019|
|Factual Accuracy sent to Applicant||01/04/2020|
|NCPE assessment recommenced||08/04/2020|
|NCPE assessment complete||15/05/2020|
|NCPE assessment outcome||The NCPE recommends that pembrolizumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.